Stock Financial Ratios, Dividends, Split History

GFN / General Finance Corp. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)198.01
Enterprise Value ($M)633.08
Book Value ($M)152.67
Book Value / Share5.71
Price / Book1.29
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Weighted Average Number Of Diluted Shares Outstanding 26,348,344
Preferred Stock Shares Outstanding 400,100
Common Stock Shares Outstanding 26,611,688
Common Shares Outstanding 26,611,688
Weighted Average Number Of Shares Outstanding Basic 26,348,344
Scoring Models
Piotroski F-Score4.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.00
Return on Assets (ROA)-0.00
Return on Equity (ROE)-0.01
Balance Sheet (mrq) ($M)
Quick Ration/a
Current Ration/a
Income Statement (mra) ($M)
Sales Revenue Goods Net100,659,000.00
Manufacturing Revenue4,895,000.00
Sales Revenue Goods Gross95,764,000.00
Operating Income19.07
Net Income-0.85
Earnings Per Share Diluted-0.25
Earnings Per Share Basic-0.25
Cash Flow Statement (mra) ($M)
Cash From Operations35.31
Cash from Investing-30.72
Cash from Financing35.31
Identifiers and Descriptors
Central Index Key (CIK)1342287

Split History

Stock splits are used by General Finance Corp. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

21h - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Related News Stories

Trinity Industries Inc.: Spin-Off Entity Does Not Look Overly Promising

2018-06-11 seekingalpha
In December 2017 Trinity Industries Inc.’s (NYSE:TRN) announced that they would spin-off their infrastructure related businesses into its own separate entity called Arcosa Inc. (Arcosa). Arcosa is expected to have approximate revenue of $1.5 billion post spin, leaving TRN with the rail-related businesses (Rail and Railcar Leasing) and approximate forecasted revenue of $2.4 billion (May 2018 Investor Presentation). (13-0)

General Finance Corp.: Cyclical Upside Has Been Realized

2018-06-01 seekingalpha
I believe that General Finance Corporation (NASDAQ:GFN) is now trading beyond its full intrinsic and an investor may want to reevaluate their position at these levels in order to lock in some gains at a price that may be a bit irrational in relation to the future economics of the business. (3-0)

General Finance's (GFN) CEO Jody Miller on Q3 2018 Results - Earnings Call Transcript

2018-05-09 seekingalpha
Welcome to the General Finance Corporation's Earnings Conference Call for the Third Quarter ended March 31, 2018. Hosting the call today from the company's corporate office in Pasadena, California are Mr. Jody Miller, President and Chief Executive Officer and Mr. Charles Barrantes, Executive Vice President and Chief Financial Officer. (3-0)

Robust Private Sector Hiring in March: 5 Top-Ranked Picks

2018-04-05 zacks
U.S. private sector employers made robust job additions in March, per a Automatic Data Processing Inc. ("ADP") and Moody’s Analytics report dated Apr 4. In fact, data from the same proved that the negative market sentiment about U.S. tariffs imposed on steel and aluminum by President Trump was overblown. Also, the U.S. Labor Department’s report released on Mar 9 showed that the economy added 313,000 jobs in February 2018, exceeding the consensus estimate of 208,000. (67-0)

Avis' (CAR) Budget Car Rental Starts Operations in Taiwan

2018-03-15 zacks
Avis Budget Group, Inc. (CAR - Free Report) , through its Budget Car Rental, has launched vehicle rental services in Taiwan. Budget Taiwan is an independently-owned and operated licensee of Budget Car Rental. It is operated by Anweisi Car Rental Company Ltd, which has years of experience in offering variety of mobility services on the island. Avis Budget’s new facilities are presently located in Taoyuan international airport, Taichung international airport, Kaohsiung international airport and Taipei’s main station. (26-0)